Open access research
Aleth (from the Greek for pure truth) is an open-access research platform focused on scientific innovation across life sciences, AI, and deep tech. Built AI-native with rigorous human oversight of the research process.
This site hosts our permanent research archive, while the live insights drop directly into your inbox. Subscribe for free via Substack to get our latest life sciences, AI and deep tech analysis the moment it’s published. Subscribe free at sub.aleth.co (opens in new tab)
ALETH / NOTES
Also this week: Trump nominated White House aide Heidi Overton to run the FDA, AstraZeneca won two late-stage lung cancer trials and stopped another, and argenx delivered a phase 3 win in myositis.
Revenue rose 10.5%, gross margin reached 62.2% and adjusted EBITDA loss more than halved; FY26 guidance includes a one-off $20m licence fee.
Also this week: Grok 4.6 brought xAI back to the frontier, AI agents breached Taiwanese government systems, and research showed encrypted reasoning traces can leak credentials and model reasoning.
Also this week: FDA proposes user-fee cuts for US trials, Jazz agrees to buy Actio for up to $1.3bn & Sionna drops a cystic fibrosis add-on drug.
Also this week: Google lines up $200bn for Anthropic, UK test recorded 19 unsanctioned model actions & EU AI Act starts biting.
Also this week: Curium Lantheus $8bn deal, Supernus Indivior $7.5bn deal, Four US biotech IPOs and Moderna's (controversial) mRNA flu shot clears the FDA.
Also this week: Anthropic's models breached outside organisations, DeepMind introduces Gemini Robotics 2 & Nvidia in talks to guarantee $250bn OpenAI funding.
Also this week: GSK chose Cambridge for its new R&D HQ, Novo's ziltivekimab fails heart trial & J&J offers $5.5bn for talc claims.
Also this week: biotech M&A hits new record, Trump threatens 200% tariffs on imported generics & Tempus AI to acquire Personalis for $1.5bn.
Also this week: Gilead agrees to buy Arcellx for $7.8bn, the FDA proposes a pathway for bespoke genetic medicines & Roche unvelied its $150 human genome Axelios sequencer at AGBT.
Danaher agrees a $9.9bn Masimo deal, an FDA NEJM article points towards one pivotal trial as the approval default, and Bayer proposes a $7.25bn Roundup settlement.
Also this week: Isomorphic Labs “well beyond AlphaFold 3”, ICON accounting probe, Lilly in vivo CAR-T bet & BridgeBio's height-improvement pill meets phase 3 goal.
Also this week: Bayer's asundexian cuts strokes 26%, the White House launches TrumpRx & two upsized US biotech IPOs got away.
Also this week: OpenAI sought $100bn from strategic investors, DeepMind published AlphaGenome in Nature and Moonshot’s Kimi K2.5 introduced a self-directed swarm of up to 100 agents.
Also this week: AZ commits $15bn to China, Roche's obesity shot hits 22.5% weight loss & Medicare picks 15 more drugs for price talks.
Also this week: Elon Musk filed for damages of $79-$134bn from OpenAI, Beijing told its tech giants to prepare H200 orders & Sam Altman courted Gulf funds for $50bn.
Also this week: GSK buys RAPT for $2.2bn, AZ leaves Nasdaq for the NYSE and Moderna pulls back from vaccine trials.
Also this week: Washington eases H200 licensing as Beijing restricts purchases, Taiwanese firms commit $250bn to US capacity & OpenAI tests ads in ChatGPT.
Also this week: Boston Scientific buys Penumbra for $14.5bn, Congress asked to codify US drug-price deals & AbbVie signs pricing deal and pledges $100bn US investment.
Also this week: Nvidia puts Vera Rubin into production, regulators close in on Grok and Anthropic reportedly raising at a $350bn valuation.
* * *
Subscribe for free to receive in your inbox at: sub.aleth.co (opens in new tab).